From the #Transfusion Evidence Round-Up: #BloodCancerAwarenessMonth 2025 #Tranexamicacid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial by the TREATT Trial Investigators https://lnkd.in/eVURBw7F

From platform to pipeline to patients. Presentations this week at #EADV2025 will demonstrate the potential of our peptide therapeutic discovery and development platform to redefine standards in psoriasis care. •In the Phase 3 ICONIC-ADVANCE 1 & 2 studies, conducted by our collaboration partner Johnson & Johnson, icotrokinra demonstrated superior skin clearance versus deucravacitinib (Sotyktu) at Weeks 16 and 24, with a similar or lower rate of adverse events. •New 52-week data from the ICONIC-LEAD study showed durable efficacy and a favorable safety profile in both adults and adolescents with moderate-to-severe plaque psoriasis. •Preclinical results for PN-881, Protagonist’s wholly owned oral IL-17 peptide antagonist, showed potent dual binding to IL-17A and IL-17F and compelling activity in disease models, supporting advancement into the clinic. We expect the first subject to be dosed in the Phase 1 single human clinical study in the coming weeks. Read more: https://lnkd.in/egAiWEZi

Gratifying to see the growing body of clinical evidence presented at #EADV2025 by our collaboration partner Johnson & Johnson and others. From Phase 3 results showing sustained skin clearance in adults and adolescents to head-to-head superiority vs. Sotyktu, icotrokinra continues to validate our belief in the potential of oral peptides to match or exceed the performance of injectable biologics. Our wholly owned investigational oral peptide, PN-881, shows potent dual inhibition of IL-17A and IL-17F, a first with an oral chemical entity, and strong efficacy in preclinical models. We look forward to advancing this candidate into first-in-human studies in the coming weeks. These programs once again reflect the power of our oral peptide platform and the strength of the collaborations and scientific rigor behind it.

🔬 We are excited to introduce the paper "The Effectiveness of Laser Applications and Photodynamic Therapy on Relevant Periodontal Pathogens (Aggregatibacter actinomycetemcomitans) Associated with Immunomodulating Anti-rheumatic Drugs". 🥼 Authored by Maria-Alexandra Martu, Ionut Luchian, Mihai Mares, Sorina Solomon, Oana Ciurcanu, Vlad Danila, Elena Rezus and Liliana Foia. 🚀 This in vitro study evaluated the antimicrobial action of a diode laser, wavelength 940 nm, and photodisinfection therapy at 670 nm (photosensitizer, 3,7 dimethyl phenothiazine chloride) on a type strain of Aggregatibacter actinomycetemcomitans, a known periodontal pathogen, in the presence and absence of active substances used in autoimmune disease therapy (Etanercept, Infliximab, Metothrexate). You may access the full article freely here 👉 https://brnw.ch/21wWgfI Please feel free to follow our LinkedIn account Bioengineering MDPI! #AntimicrobialResistance #Periodontitis #Immunomodulators #DMARDS #PhotodynamicTherapy

MannKind is proud to share that “Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease” (NTM) was published ahead of print in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. Underway globally, the ICoN-1 phase 3 clinical trial is designed to evaluate the efficacy and safety of Inhaled Clofazimine (MNKD-101) on top of guideline-based therapy. Read more: https://bit.ly/4gGHt7K

It's great to share a bit more about ThirtyFiveBio's innovative approach to treating ulcerative colitis (UC). Current medicines pose limited benefit for UC patients, with most patients being non-responders and many relapsing. By inhibiting GPR35, ThirtyFiveBio are addressing the underlying disease causality by resolving dysfunction in the gut epithelium, thereby reducing inflammation and preventing flare-ups or disease progression. If you're not already, why not follow us along on this journey to create life-changing medicines for those who need them? #UlcerativeColitis #DrugDevelopment #GPR35 #ThirtyFiveBio

Great progress from the Molecule to Medicine and ThirtyFiveBio team, with the continued support of our investors AbbVie Ventures, Canaan and Mayewell Capital, LLC. Our epithelial biology and science points to the potential of GPR35 antagonism overcoming the clinical response threshold experienced by people with GI autoimmune disease on current and emerging anti-inflammatories.

With limited treatment options, endometriosis is a painful disorder that affects 190 million women globally. I had the chance to speak with Gesynta Pharma AB CEO Patric Stenberg about the company's non-hormonal candidate vipoglanstat, which is entering a Phase II trial for the disease. What makes this drug different from existing therapies is it is designed to actually shrink endometrial lesions, not just mask the pain, and it does so without affecting hormone levels. The approach is clever: targeting mPGES-1 enzyme inhibition reduces inflammation while boosting protective prostacyclin levels. In preclinical studies, they saw both pain relief and lesion reduction - a rare combination in this space. Phase I data showed strong target engagement and a safe profile. Their Phase II will track 190 patients across Europe using MRI imaging to measure lesion changes alongside pain scores. It's an ambitious study design that reflects real confidence in the mechanism. With existing therapies running $14K+ annually and often forcing women into early menopause, there's clearly room for innovation here. At the same time, Organon's recent Phase II failure reminds us how challenging this indication is for drug developers. Gesynta raised $36.9M to fund the trial, with topline data expected mid-2027. #WomensHealth #Endometriosis #SwedishBiotech Citeline https://lnkd.in/gVvNnpZC

Sonelokimab (SLK) is an innovative #nanobody featuring three VHH domains that bind to IL-17A, IL-17F, and albumin. Psoriatic arthritis (PsA) is a progressive, multidomain disease linked to interleukin-17 (IL-17) that can lead to significant quality-of-life deficits. Recent research has revealed SLK's potential in treating PsA. In a phase 2 #trial, participants receiving SLK experienced substantial improvements in both skin and joint symptoms. By week 12, those on SLK showed notable benefits over placebo, achieving key targets like ACR70 and PASI 100, as well as complete nail clearance. By week 24, up to 62% of patients reached minimal disease activity. It looks like another nanobody could be getting FDA approval soon! Authors: Iain B. McInnes, Laura C. Coates, Philip J. Mease, Alexis Ogdie, Arthur Kavanaugh, Lihi Eder, Georg Schett, Alan Kivitz, Dennis McGonagle, Nuala Brennan, Alex Godwood, Eva Cullen, Kristian Reich, Christopher T. Ritchlin & Joseph F. Merola Full study: https://lnkd.in/gxf7irGd #clinicaltrial #singledomainantibody #biotech

Abbott is proud to announce the CE mark for the 𝘪-𝘚𝘛𝘈𝘛 𝘛𝘉𝘐 cartridge, a dual brain-specific biomarkers, whole blood test to help assess mild traumatic brain injuries at the point of care. Did you know Abbott is the only company in the world to offer three different FDA-cleared blood tests to help assess traumatic brain injuries (TBI)? 1.) i-STAT TBI Plasma Test: A rapid, handheld test using plasma, providing results in 15 minutes. 2.) i-STAT TBI Whole Blood Test: Recently cleared for bedside use with whole blood, expanding accessibility. 3.) Alinity i TBI Lab Test: A lab-based test that runs on Abbott’s Alinity® i platform, offering results in 18 minutes. Learn more: https://lnkd.in/gKfV2UyH #PointofCare #POC #mTBI #Innovation #Abbott #ProudtobeAbbott #AbbottProud #IWorkatAbbott #LifetotheFullest #Diagnostics #LaboratoryMedicine